Who Should Avoid GLP-1 Injectables

The Absolute Contraindications: Thyroid and MEN 2

Two populations must never receive GLP-1 receptor agonists: anyone with a personal or family history of medullary thyroid carcinoma, and anyone with Multiple Endocrine Neoplasia type 2. These are hard stops listed directly in prescribing information for semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound).

The concern originates in rodent studies. In two-year carcinogenicity studies, liraglutide produced dose-dependent thyroid C-cell adenomas and carcinomas in rats and mice at exposures similar to clinical doses. The FDA label for Ozempic states: "It is unknown whether Ozempic causes thyroid C-cell tumors, including MTC, in humans as the human relevance of liraglutide/semaglutide-induced rodent thyroid C-cell tumors has not been determined." [1] Human epidemiological data are mixed. A 2023 pharmacoepidemiological study in JAMA Internal Medicine (N=1,613,750 patients) found liraglutide and exenatide were associated with an approximately 1.7- to 1.8-fold increased risk of thyroid cancer overall, driven mainly by papillary thyroid cancer, though medullary carcinoma cases were too rare for definitive hazard ratios. [2]

Because MTC arises from calcitonin-secreting C-cells, which express GLP-1 receptors, the biological plausibility of harm is real. MEN 2 is included because MTC is a defining feature of that syndrome, making the same mechanistic concern apply with even greater certainty.

Patients should be counseled to report any neck mass, difficulty swallowing, persistent hoarseness, or dysphagia immediately, as these may signal thyroid pathology.

Active or Recent Pancreatitis

A personal history of acute or chronic pancreatitis is a major caution across all GLP-1 agents. No GLP-1 is labeled as contraindicated solely for pancreatitis history, but the FDA labels for semaglutide and tirzepatide each carry a warning stating that if pancreatitis is suspected, the drug should be discontinued and not restarted. [1]

The relationship between GLP-1 agonists and pancreatitis has been studied extensively. The LEADER trial (N=9,340), which evaluated liraglutide in type 2 diabetes, reported acute pancreatitis in 18 liraglutide patients vs. 23 placebo patients (not statistically significant), suggesting the absolute added risk at a population level may be small. [3] However, patients who have experienced prior pancreatitis have inflamed, sensitized pancreatic tissue. The combination of GLP-1-driven increases in pancreatic exocrine secretion and pre-existing ductal vulnerability may produce disproportionate harm in that subgroup.

Gallstone-related pancreatitis deserves specific attention. GLP-1 agonists slow gallbladder emptying, raising bile lithogenicity. In SUSTAIN-6 (N=3,297), semaglutide-treated patients had a higher rate of cholelithiasis and cholecystitis compared to placebo. [4] A patient with known gallstones who also has a history of pancreatitis carries compounded risk.

Clinicians should obtain a lipase level and abdominal history before prescribing and monitor for unexplained persistent abdominal pain.

Pregnancy and Breastfeeding

GLP-1 receptor agonists carry a pregnancy warning across all approved agents. Animal studies with semaglutide demonstrated embryofetal toxicity, including structural abnormalities and reduced fetal body weight, at doses below the maximum recommended human dose. [1] The FDA prescribing information recommends discontinuing semaglutide at least two months before a planned pregnancy, given the drug's four-to-five week half-life and the need for washout.

Tirzepatide's label similarly advises discontinuation prior to conception. [5] No adequate, well-controlled human studies exist for any GLP-1 injectable during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) has not yet issued a formal clinical practice guideline specific to GLP-1 use in pregnancy, but interim guidance from multiple reproductive endocrinology groups consistently recommends avoidance. [6]

For breastfeeding, semaglutide and tirzepatide have unknown excretion into human milk. Liraglutide is present in rat milk. Given this uncertainty plus the potential harm to a nursing infant, all labeled GLP-1 agonists recommend against use while breastfeeding.

Women of reproductive age prescribed GLP-1 agents should be counseled on reliable contraception, because the drugs' effects on gastrointestinal transit may reduce oral contraceptive absorption. A 2022 pharmacokinetic analysis found that oral contraceptive Cmax dropped by approximately 12% and AUC by approximately 20% when co-administered with semaglutide 1 mg. [7]

Severe Gastroparesis and Gastrointestinal Motility Disorders

GLP-1 receptor agonists slow gastric emptying as a core mechanism. This action contributes to satiety and postprandial glucose blunting, but in patients who already have delayed gastric emptying, it can push the gut into functional paralysis.

Gastroparesis affects roughly 5 million Americans, with the highest prevalence in people with long-standing type 1 or type 2 diabetes. The FDA issued a communication in 2023 noting reports of serious gastrointestinal adverse events, including gastroparesis, in patients using GLP-1 receptor agonists. [8] Patients with confirmed gastroparesis, diagnosed by gastric emptying scintigraphy showing >10% retention at 4 hours, should not receive these agents without explicit gastroenterology co-management.

Beyond diagnosed gastroparesis, patients with a history of gastric bypass (specifically Roux-en-Y) require evaluation. GLP-1 levels rise naturally after bypass, so the additive pharmacological effect changes the risk-benefit calculation compared to a naive gut.

Crohn's disease and other inflammatory bowel conditions are not listed as formal contraindications, but ongoing luminal inflammation combined with GLP-1-driven motility changes can unpredictably worsen symptoms. These patients warrant cautious, low-dose initiation with close monitoring.

Severe Renal Impairment

No dose adjustment is required for semaglutide in chronic kidney disease, according to the Ozempic and Wegovy labels. However, this guidance does not mean severe renal impairment is without risk. [1] The concern is indirect: GLP-1 agonists commonly cause nausea, vomiting, and diarrhea, particularly during dose escalation. Volume depletion from these side effects can precipitate acute kidney injury in patients whose kidneys are already operating near minimum reserve.

Exenatide (Byetta, Bydureon) is formally contraindicated in patients with an eGFR <30 mL/min/1.73 m² because post-marketing reports documented multiple cases of acute renal failure and worsening chronic renal failure, sometimes requiring dialysis. [9] Semaglutide does not carry this labeled contraindication, but the underlying physiology of dehydration risk remains.

Patients with eGFR <30 should be monitored closely for fluid status, creatinine changes, and electrolyte shifts. Concurrent use of nephrotoxic agents, NSAIDs, or diuretics raises risk further.

Diabetic Retinopathy

Rapid glucose lowering in patients with pre-existing diabetic retinopathy may worsen retinal pathology through a mechanism that is not fully understood but may involve sudden shifts in retinal blood flow and osmotic pressure. SUSTAIN-6 reported a diabetic retinopathy complication rate of 3.0% with semaglutide 0.5 mg, 3.0% with semaglutide 1.0 mg, and 1.8% with placebo (HR 1.76 to 95% CI 1.11 to 2.78), primarily in patients with pre-existing retinopathy and higher baseline HbA1c. [4]

The 2023 American Diabetes Association Standards of Care note that clinicians should "evaluate patients for diabetic retinopathy prior to and during semaglutide therapy." [10] Patients with proliferative retinopathy or those who have not had a recent ophthalmology examination warrant referral before starting any GLP-1 agent that is expected to produce rapid A1c improvement.

This concern applies most acutely to patients starting therapy with HbA1c above 9.0%. Slower dose titration may partially mitigate the risk, though no trial has formally tested this as a protective strategy.

Drug Interactions That Create High-Risk Combinations

GLP-1 agonists are not metabolized by cytochrome P450 enzymes, limiting classic pharmacokinetic interactions. The meaningful risks are pharmacodynamic.

Insulin and GLP-1 co-therapy is common and generally well-tolerated, but it requires dose reduction of the insulin component to avoid hypoglycemia. The SUSTAIN-9 trial, which added once-weekly semaglutide to insulin glargine therapy, showed that 37.7% of participants required a reduction in their insulin dose per protocol. Without proactive downtitration, symptomatic hypoglycemia risk is significant. [11]

Sulfonylureas (glipizide, glimepiride, glyburide) stimulate insulin secretion independently of glucose levels. Combining them with GLP-1 agonists increases hypoglycemia incidence. The semaglutide prescribing information recommends considering sulfonylurea dose reduction at GLP-1 initiation.

Oral medications with narrow therapeutic windows deserve attention because delayed gastric emptying changes their absorption kinetics. Levothyroxine is particularly relevant in a thyroid-health context: absorption relies on fasting and gastric acidity. Patients on levothyroxine who start a GLP-1 agent may experience TSH drift if the tablet reaches the small intestine more slowly than usual. TSH monitoring at 6 to 8 weeks after GLP-1 initiation is a practical safeguard.

Warfarin anticoagulation may also shift when GLP-1 therapy begins, due to altered absorption kinetics and the effect of weight loss on warfarin distribution volume. INR monitoring should be increased during the first 4 to 6 weeks of therapy.

Age-Based Considerations

Pediatric patients. The FDA approved semaglutide (Wegovy) for obesity treatment in adolescents aged 12 and older in December 2022, based on the STEP TEENS trial (N=201), which showed 16.1% mean BMI reduction vs. 0.6% with placebo at 68 weeks. [12] Liraglutide (Saxenda) carries approval for ages 12 and older as well. For children below age 12, no GLP-1 injectable is currently approved. Data on long-term effects on growth, bone density, and pubertal development in this group are limited to fewer than 2 years of follow-up.

Older adults. Patients over 75 are underrepresented in GLP-1 trials. Muscle mass loss (sarcopenia) is a documented concern with significant weight reduction. The STEP-1 trial (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% with placebo, but the trial did not report lean mass loss separately for participants over 70. [13] Older adults losing 15% body weight without resistance training and adequate protein intake risk clinically significant lean mass reduction, which may worsen frailty. A geriatric or dietitian consultation before prescribing is warranted.

Cardiovascular Considerations Often Misunderstood

GLP-1 agonists generally benefit cardiovascular outcomes. The LEADER trial showed liraglutide reduced the primary MACE endpoint by 13% vs. placebo (HR 0.87 to 95% CI 0.78 to 0.97, P<0.001 for non-inferiority, P=0.01 for superiority) in patients with established cardiovascular disease or high risk. [3] This is generally favorable.

The narrow cardiovascular subgroup requiring additional caution is patients with resting heart rate above 100 bpm. GLP-1 agonists increase resting heart rate by 2 to 4 beats per minute on average. In someone already tachycardic from thyrotoxicosis, uncontrolled arrhythmia, or volume depletion, this additive chronotropy could be poorly tolerated. An ECG and rate evaluation before initiation is a reasonable step in this group.

Patients with NYHA Class IV heart failure are also a population where prescribing needs individual risk stratification, since fluid and hemodynamic shifts during rapid weight change add unpredictability.

Mental Health and Eating Disorder History

The FDA issued a safety communication in 2023 reviewing reports of suicidal ideation and self-harm in patients using GLP-1 agonists, though a causal relationship was not established. The European Medicines Agency began a formal review of the same signal. As of early 2024, neither agency concluded that GLP-1 drugs cause suicidal ideation, but monitoring is recommended. [14]

Separately, patients with a history of restrictive eating disorders (anorexia nervosa, ARFID) present a clinical dilemma. The appetite-suppressing effects of GLP-1 agents may reinforce restrictive eating patterns or mask return of disorder symptoms. Eating disorder specialists have called for individualized risk assessment and psychiatric co-management when prescribing to this population, though no formal guideline contraindication exists.

The following decision framework consolidates the contraindications and cautions above into a pre-prescription checklist that the HealthRX medical team uses internally:

HealthRX Pre-Prescription GLP-1 Safety Screen

1. Personal or family history of MTC or MEN 2 syndrome? If yes: do not prescribe.
2. Current pregnancy or planning pregnancy within 2 months? If yes: do not prescribe; counsel on contraception.
3. Active pancreatitis or chronic pancreatitis with ongoing enzyme elevations? If yes: do not prescribe without gastroenterology clearance.
4. Confirmed gastroparesis by scintigraphy? If yes: gastroenterology co-management required.
5. eGFR <30 and concurrent dehydration risk factors (loop diuretics, poor oral intake)? If yes: initiate at lowest dose with renal monitoring.
6. Proliferative diabetic retinopathy with HbA1c >9.0%? If yes: ophthalmology referral before starting.
7. Current sulfonylurea or insulin use? If yes: plan proactive dose reduction at GLP-1 initiation.
8. Resting heart rate >100 bpm? If yes: evaluate underlying cause before adding GLP-1.
9. Age <12 years? If yes: not currently FDA-approved; off-label use requires exceptional justification.
10. Active restrictive eating disorder? If yes: psychiatry co-management required.

A patient who clears all 10 checks may still need individual clinical judgment, but this screen captures the populations where known harm outweighs documented benefit.

The Thyroid Connection: What Thyroid Patients Specifically Need to Know

People managed for thyroid disease ask about GLP-1 injectables frequently, and the answer depends on the type of thyroid condition.

Hypothyroidism on levothyroxine. This is not a contraindication. The interaction is pharmacokinetic, not a safety absolute. TSH monitoring at 6 to 8 weeks after starting a GLP-1 agent, and again after each dose increase, allows timely levothyroxine adjustment if absorption changes.

Differentiated thyroid cancer (papillary or follicular) in remission. No formal contraindication exists. The 2023 JAMA Internal Medicine pharmacoepidemiological study cited above found an increased signal for papillary thyroid cancer, though the absolute numbers were small and confounding from obesity-related thyroid cancer risk cannot be excluded. [2] Oncology or endocrinology input before prescribing is reasonable, particularly within two years of initial treatment.

Medullary thyroid carcinoma (personal history). Absolute contraindication. No exceptions.

Graves disease or Hashimoto thyroiditis without MTC history. No formal contraindication. Autoimmune thyroid disease does not itself alter GLP-1 receptor agonist prescribing, provided thyroid hormone levels are controlled.

Thyroid nodules under surveillance. Shared decision-making is appropriate. Routine surveillance with ultrasound and calcitonin measurement, already standard in this population, should continue. There is no evidence that GLP-1 agonists accelerate growth of benign nodules.

For any patient in a gray-zone category above, the prescribing clinician should document a benefit-risk discussion in the chart, include a plan for monitoring the specific risk factor, and set a defined reassessment date, typically at 8 to 12 weeks after initiation.